Soft Drink and Juice Consumption and Renal Cell Carcinoma Incidence and Mortality in the European Prospective Investigation into Cancer and Nutrition.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
06 2021
Historique:
received: 07 12 2020
revised: 17 02 2021
accepted: 01 04 2021
pubmed: 15 4 2021
medline: 27 1 2022
entrez: 14 4 2021
Statut: ppublish

Résumé

Renal cell carcinoma (RCC) accounts for more than 80% of kidney cancers in adults, and obesity is a known risk factor. Regular consumption of sweetened beverages has been linked to obesity and several chronic diseases, including some types of cancer. It is uncertain whether soft drink and juice consumption is associated with risk of RCC. We investigated the associations of soft drink and juice consumption with RCC incidence and mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC). A total of 389,220 EPIC participants with median age of 52 years at recruitment (1991-2000) were included. Cox regression yielded adjusted HRs and 95% confidence intervals (CI) for RCC incidence and mortality in relation to intakes of juices and total, sugar-sweetened, and artificially sweetened soft drinks. A total of 888 incident RCCs and 356 RCC deaths were identified. In models including adjustment for body mass index and energy intake, there was no higher risk of incident RCC associated with consumption of juices (HR per 100 g/day increment = 1.03; 95% CI, 0.97-1.09), total soft drinks (HR = 1.01; 95% CI, 0.98-1.05), sugar-sweetened soft drinks (HR = 0.99; 95% CI, 0.94-1.05), or artificially sweetened soft drinks (HR = 1.02; 95% CI, 0.96-1.08). In these fully adjusted models, none of the beverages was associated with RCC mortality (HR, 95% CI per 100 g/day increment 1.06, 0.97-1.16; 1.03, 0.98-1.09; 0.97, 0.89-1.07; and 1.06, 0.99-1.14, respectively). Consumption of juices or soft drinks was not associated with RCC incidence or mortality after adjusting for obesity. Soft drink and juice intakes are unlikely to play an independent role in RCC development or mortality.

Sections du résumé

BACKGROUND
Renal cell carcinoma (RCC) accounts for more than 80% of kidney cancers in adults, and obesity is a known risk factor. Regular consumption of sweetened beverages has been linked to obesity and several chronic diseases, including some types of cancer. It is uncertain whether soft drink and juice consumption is associated with risk of RCC. We investigated the associations of soft drink and juice consumption with RCC incidence and mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC).
METHODS
A total of 389,220 EPIC participants with median age of 52 years at recruitment (1991-2000) were included. Cox regression yielded adjusted HRs and 95% confidence intervals (CI) for RCC incidence and mortality in relation to intakes of juices and total, sugar-sweetened, and artificially sweetened soft drinks.
RESULTS
A total of 888 incident RCCs and 356 RCC deaths were identified. In models including adjustment for body mass index and energy intake, there was no higher risk of incident RCC associated with consumption of juices (HR per 100 g/day increment = 1.03; 95% CI, 0.97-1.09), total soft drinks (HR = 1.01; 95% CI, 0.98-1.05), sugar-sweetened soft drinks (HR = 0.99; 95% CI, 0.94-1.05), or artificially sweetened soft drinks (HR = 1.02; 95% CI, 0.96-1.08). In these fully adjusted models, none of the beverages was associated with RCC mortality (HR, 95% CI per 100 g/day increment 1.06, 0.97-1.16; 1.03, 0.98-1.09; 0.97, 0.89-1.07; and 1.06, 0.99-1.14, respectively).
CONCLUSIONS
Consumption of juices or soft drinks was not associated with RCC incidence or mortality after adjusting for obesity.
IMPACT
Soft drink and juice intakes are unlikely to play an independent role in RCC development or mortality.

Identifiants

pubmed: 33849969
pii: 1055-9965.EPI-20-1726
doi: 10.1158/1055-9965.EPI-20-1726
pmc: PMC7611361
mid: EMS128699
doi:

Substances chimiques

Sweetening Agents 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1270-1274

Subventions

Organisme : Cancer Research UK
ID : 24390
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A29017
Pays : United Kingdom

Informations de copyright

©2021 American Association for Cancer Research.

Références

Public Health Nutr. 2018 Jun;21(9):1618-1626
pubmed: 29463332
Eur J Cancer Prev. 2014 Sep;23(5):481-90
pubmed: 24625472
Br J Cancer. 2011 Apr 26;104(9):1487-92
pubmed: 21407222
Obes Facts. 2017;10(6):674-693
pubmed: 29237159
Int J Cancer. 2007 Nov 15;121(10):2246-53
pubmed: 17583573
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
BMJ. 2018 Feb 14;360:k322
pubmed: 29444771
JAMA Intern Med. 2019 Nov 1;179(11):1479-1490
pubmed: 31479109

Auteurs

Alicia K Heath (AK)

School of Public Health, Imperial College London, London, United Kingdom. a.heath@imperial.ac.uk david.muller@imperial.ac.uk.

Joanna L Clasen (JL)

School of Public Health, Imperial College London, London, United Kingdom.

Nick P Jayanth (NP)

School of Public Health, Imperial College London, London, United Kingdom.

Mazda Jenab (M)

International Agency for Research on Cancer (IARC-WHO), Lyon, France.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Kristina Elin Nielsen Petersen (KEN)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Kim Overvad (K)

Department on Public Health, Aarhus University, Aarhus, Denmark.

Bernard Srour (B)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Verena Katzke (V)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Manuela M Bergmann (MM)

German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany.
Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy.

Vittorio Krogh (V)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7) Ragusa, Italy.

Alberto Catalano (A)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Fabrizio Pasanisi (F)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.

Magritt Brustad (M)

UiT The Arctic University of Norway, Tromsø, Norway.

Karina Standahl Olsen (KS)

UiT The Arctic University of Norway, Tromsø, Norway.

Guri Skeie (G)

UiT The Arctic University of Norway, Tromsø, Norway.

Leila Luján-Barroso (L)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Miguel Rodríguez-Barranco (M)

Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.

Carmen Santiuste (C)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.

Aurelio Barricarte Gurrea (A)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA) Pamplona, Spain.

Håkan Axelson (H)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Stina Ramne (S)

Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.

Börje Ljungberg (B)

Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.

Eleanor L Watts (EL)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Inge Huybrechts (I)

International Agency for Research on Cancer (IARC-WHO), Lyon, France.

Elisabete Weiderpass (E)

International Agency for Research on Cancer (IARC-WHO), Lyon, France.

Elio Riboli (E)

School of Public Health, Imperial College London, London, United Kingdom.

David C Muller (DC)

School of Public Health, Imperial College London, London, United Kingdom. a.heath@imperial.ac.uk david.muller@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH